Stem Pharm
Stem Pharm: Trusted supplier of synthetic biomaterials for advanced cellular models and regenerative medicine.
Founded
2015Stem Pharm: Trusted supplier of synthetic biomaterials for advanced cellular models and regenerative medicine.
Stem Pharm, founded in 2015, is dedicated to supplying synthetic biomaterials tailored for advanced cellular models in drug discovery and regenerative medicine. The company focuses on engineering human biology to redefine neurologic drug discovery and modeling neuroinflammatory diseases with advanced in vitro models. Their offerings include human neural organoids with microglia for neuroimmune drug discovery, synthetic substrates like chemically-defined hydrogels, and comprehensive drug discovery services encompassing neurologic disease modeling, target discovery, phenotypic drug screening, and neurotoxicity assessments.
Stem Pharm has made significant strides in the field of synthetic biomaterials, becoming a trusted partner for researchers and pharmaceutical companies. Their innovative products and services have facilitated advancements in neurologic drug discovery and regenerative medicine, contributing to more effective and targeted therapeutic solutions. The company's impact is evident in its collaborations and partnerships that drive forward the understanding and treatment of complex neuroinflammatory diseases.
Companies similar to Stem Pharm include BrainXell, Stemina Biomarker Discovery, NeuCyte and Humabiologics.
Stem Pharm was founded in 2015.
Stem Pharm's headquarters is located in Madison, WI, US.
Stem Pharm's most recent funding round was for $10k (USD) in May 2023.
As of May 30, 2023, Stem Pharm has disclosed funding of $683.3k (USD). Undisclosed round amounts are excluded.
Stem Pharm has 6 employees as of Feb 4, 2024.
Humabiologics
humabiologics.com
